Medical Device | March 12, 2026
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
The FDA classified LifeVac as a Class II medical device
The FDA classified LifeVac as a Class II medical device
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Under the deal, Quiver will receive an undisclosed advance payment and research support
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Subscribe To Our Newsletter & Stay Updated
